
I became addicted to beauty regime after ‘feeling accepted' but now I'm paying the price – don't make same mistake
A WOMAN has issued a stark warning after a beauty regime she started in her twenties left her needing 19 vital treatments, saying: "I didn't know the damage I was doing".
Karrieann McDonnell, from Co Clare, is urging young people not to make the same mistake, or they may regret it in future years.
3
3
3
The 54-year-old fitness fanatic told how she first tried sunbeds as she wanted to look the part for her job.
She said: "When I started out on the sunbed when I was in my late twenties, I was a strawberry blonde, fair skinned with freckles.
"When I got into the fitness industry then, we had a sunbed on the premises.
"It became very popular as it would have been back then in those days.
"And being young and impressionable, you want to be part of the team but having fair skin and freckles wasn't the look back then.
"When you're in fitness, it's about looking good, it's about feeling confident. It's all about the image and having that sun-kissed glow.
"I taught a lot of classes, I was on stage we'll say. So like any performer, you have to look good.
"When I started out, I was quieter, I was a mother, I was a parent, you know, a family woman who grew up quiet in herself.
"And then as time kind of went on, I became popular. And I thought, 'Oh, OK, so I have to look this good to be accepted'.
And Karrieann gradually built up the time she was spending under the lamp in a bid to get the best results.
MAINTAIN COLOUR
She added: "When I started out on the sunbed, it would have been like five minutes to start.
"That went on for a couple of weeks and I was going nowhere fast.
"So then I went on to six minutes, eight minutes, ten minutes and again, that was over the time.
"Over the years then, I had built it up to 20 minutes, and that would have been maybe twice a week, once a week, depending on the time of year.
"It would have been weekly because being so fair, I had to keep doing them to maintain some sort of colour.
"But little did I know the damage I was doing because the knowledge wasn't there.
"Everyone's skin is different and if you have dark skin you're going to tan better.
"You're going to take to the sun differently compared to someone who's fair."
SKIN OPS
Karrieann has dealt with the damage caused by sunbeds over the last few years.
She said: "I have had 19 different melanomas removed, be that from surgery, the light treatment, and then nitrogen freeze.
"They're all melanomas, but just different stages of them.
"They're also called BCCs, which is basal cell carcinoma, and skin damage is caused by BCCs from overuse of either UV or too much sun.
"And if they're not treated they grow deeper into your skin hence the growths that you have on your body.
"But when you have women, we're all about our appearance if we're all honest and in particular our face.
NO SPF
"All the money we spend on creams for our face and SPF has only come out in the last how many years.
"When I started wearing makeup when I was 14, what was SPF? There was no such thing.
"That really didn't come out, I suppose, until the 90s and maybe the early 2000s. All because social media has created 'SPF this' and 'SPF that' and 'mind your face and all that'.
"But when you're 18 and impressionable and 20 onwards, you don't know what SPF is.
"You don't know how to mind your skin until you get later in life."
KEY SIGNS OF MELANOMA
THE most common sign of melanoma is the appearance of a new mole or a change in an existing mole.
Most experts recommend using the simple 'ABCDE' rule to look for symptoms of melanoma skin cancer, which can appear anywhere on the body.
Asymmetrical – melanomas usually have two very different halves and are an irregular shape
Border – melanomas usually have a notched or ragged border
Colours – melanomas will usually be a mix of two or more colours
Diameter – most melanomas are usually larger than 6mm in diameter
Enlargement or elevation – a mole that changes size over time is more likely to be a melanoma
And she said if she could turn back time she wouldn't have touched a sunbed.
She added: "I mean, when you're young, you're not going to be told and you're not going to listen. You're going to have to find out the hard way.
"And unfortunately, that's not going to happen until later life, because if I had known then what I know now, I most certainly wouldn't have done the damage that I have done to myself.
"But luckily I have been fortunate that I haven't had cancer, but the skin damage that I have, I won't say that I like it. I have it. I do try to get treatments done with it."
'TAN FADES, DAMAGE DOESN'T'
Karrieann said she now opts for fake tan instead, saying "tan fades, damage doesn't".
She said: "Some days when I put tan on, it looks worse than other days, and because I do try to tone it down as much as I can.
"Because, let's face it, who likes looking at leathery, botched up skin when you'd really rather love to have silky smooth beautiful skin.
"That's where age comes into it, when you're doing all these sunbeds when you're younger and you're not aware of the damage, but if you are aware, all good and well.
"But when you're not aware, a lot of young ladies have approached me over the last few weeks, and thanked me for bringing the awareness.
"Some of them actually have decided not to do any more sunbeds, but I've clearly said to them, 'I'm not telling you to do anything'.
"I said, 'I'm just bringing the awareness, you still have the choice to make yourself.'"
STATS
Health chiefs said that about 11,000 people are diagnosed with skin cancer each year.
And it is the most common cancer in Ireland.
However, a recent report published by the National Cancer Registry Ireland shows that the survival rate for most cases is nearly 100 per cent.
It says that about 9 out of 10 cases are non-melanoma skin cancers, and other types include melanoma.
Men are more likely to die from skin cancer than women, and about 270 people die from skin cancer each year in Ireland.
Director of the National Cancer Registry, Prof. Deirdre Murray, said: "Understanding the trends in skin cancer is vital for public health awareness and prevention strategies.
"Many of these cancers could be prevented with wider adoption of safe sun practices in our population and avoidance of sunbeds."
Skin cancer is more common in people over 50 but you can get melanoma skin cancer at any age.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Daily Mail
28 minutes ago
- Daily Mail
Back pain can be eased with walking – but there's a specific number of minutes to reach per day
Hitting 10,000 steps a day is a goal for millions of us. But the number of minutes we walk for may be a more important target to focus on. Scientists believe being on your feet for over an hour-and-a-half every day could slash the risk of chronic lower back pain. Norwegian and Danish researchers found people who walk for over 100 minutes a day cut this risk by almost a quarter compared to those who clocked 78 minutes per day or less. They also discovered faster walkers were less likely to have chronic back pain—but the effect was less pronounced than walking for longer. Experts, who labelled the findings important, urged policy makers to push walking as a 'public health strategy' to reduce the risk of the agonising condition. In many cases, lower back pain starts suddenly and improves within a few days or weeks. But if it sticks around for more than three months, it's classed as chronic, according to the NHS. In some cases, it can be considered a disability. In the study, 11,194 Norwegians, with an average age of 55, were quizzed on their health and how much exercise they did per week. Almost a sixth (14.8 per cent) reported suffering from lower back pain, answering 'yes' to the following questions, 'During the last year, have you had pain and/or stiffness in your muscles or joints that lasted for at least three consecutive months? and 'Where have you had this pain or stiffness?' Participants were considered to have the condition if they answered yes to the first question and reported pain in the lower back to the second. Both men and women were involved in the study, and 100 minutes was found to be the optimum length of time for both sexes, and all ages. Writing in the journal JAMA Network Open, the researchers concluded: 'Compared with walking less than 78 minutes per day, those who walked more than 100 minutes per day had a 23 per cent reduced risk of chronic lower back pain. 'The reduction in risk of chronic lower back pain leveled off beyond a walking volume of about 100 minutes per day. 'Our findings suggest that daily walking volume is more important than mean walking intensity in reducing the risk of chronic lower back pain. 'These findings suggest that policies and public health strategies promoting walking could help to reduce the occurrence of chronic lower back pain.' The researchers also noted that their results are 'likely generalisable beyond the Norwegian adult population, as physical inactivity prevalence in Norway is comparable to that observed in other high-income countries'. They did note some limitations of the study, including that participants with higher walking volume tended to exercise more often and reported higher physical work demands, which might give them a physical advantage over other members of the group. In the UK, musculoskeletal conditions (MSK)—including back pain—are the second biggest reason for people being 'economically inactive'—where someone is out of work and not looking for work. Figures released by the Government in December 2024 revealed that MSK conditions affect approximately 646,000 Britons, 1-in-4 of the 2.8m who are claiming long-term sickness benefits. MSK comes second only to mental health issues for reasons why people are unable to work. It was estimated that 23.4 million working days in the UK were lost due to MSK conditions in 2022. NHS waiting lists for MSK community services are the highest of all community waits in England, with 348,799 people in September 2024 waiting to see a specialist. As part of their Get Britain Working White Paper, the Government pledged a £3.5million package to 17 Integrated Care Boards (ICBs) across England to improve local MSK services.


Telegraph
2 hours ago
- Telegraph
US tells states: Follow Cass Review in treatment of ‘trans' children
The US government is pressuring states to halt funding for puberty blockers for children and follow the UK's Cass Review. The Center for Medicare and Medicaid Services (CMS), which provides health coverage to more than 160 million Americans, urged directors to adopt the findings of the report, which concluded children who think they are transgender should not be rushed into treatment they may regret. In a letter sent to medical directors, seen by The Telegraph, the agency said that Britain has 'diverged' from the United States and that the National Health Service's new approach is more effective. Under Donald Trump, the US has quickly moved to ban all 'destructive and life-altering procedures' associated with transitioning children. Some 27 states have enacted laws that ban or restrict gender‑affirming care for minors. But puberty blockers are still available in many others. 'Several developed countries have recently diverged from the US in the way they treat gender dysphoria in children,' the letter reads. 'The United Kingdom, Sweden, and Finland have recently issued restrictions on medical interventions for children, including the use of puberty blockers and hormone treatments. 'In particular, the Cass Review, an independent review of the evidence in the United Kingdom, noted that despite the considerable research in the field of gender dysphoria in children, 'systematic evidence reviews demonstrated the poor quality of the published studies, meaning there is not a reliable evidence base upon which to make clinical decisions, or for children and their families to make informed choices.'' Led by Dr Hilary Cass, the review was prompted by concerns about the high rate of young people being referred to the Tavistock gender clinic in London, which referred children as young as 10 for treatment with puberty blockers. The final review, released in April 2024, concluded that too many children were being pushed towards medication with not enough mental health care. Dr Cass recommended that the most important treatment for the majority of children should be talking therapies instead of irreversible medical treatments such as puberty blockers. The letter went on to imply Britain is more effective in upholding the US government's commitment to 'do no harm to America's children'. 'In recent years, medical interventions for gender dysphoria in children have proliferated,' the letter added. 'These interventions include surgical procedures that attempt to transform an individual's physical appearance to align with an identity that differs from his or her sex or that attempt, for purposes of treating gender dysphoria, to alter or remove an individual's sexual organs to minimise or destroy their natural biological functions.' The letter also said medical interventions for gender dysphoria in children have 'proliferated' in America and the Cass Review, which is rumoured to be backed by Mr Trump, could be used by states to reduce cases. The move is a rare example of British policy influencing American direction under Mr Trump, who moved to ban puberty blockers almost immediately upon arriving in the White House. His administration has largely been critical of Britain's policies, repeatedly raising concerns about free speech. In May, The Telegraph revealed the president had sent a delegation to meet British anti-abortion activists who say their freedom of expression has been threatened. A five-person team from the US State Department spent several days in the country and interviewed campaigners. Trump has intervened on transgender issues Trans activists have long fought to retain puberty blockers as a treatment option for children with gender dysphoria. Democratic attorneys general in Washington, Oregon and Minnesota sued the Trump administration over its plans to pull funding from institutions that provide gender-affirming care. The US president has signed a number of executive orders targeting transgender people, claiming that it is a radical ideology driven to 'deny the biological reality of sex'. In January, he signed an order that aimed to restrict gender-affirming treatments for all young people below the age of 19 by asking federal agencies to stop endorsing interventions such as puberty blockers, hormone therapy, and surgery for minors. In July 2024, The Integrity Project at Yale Law School released a white paper which said the Cass Review had 'serious flaws'. It suggested that the review 'levies unsupported assertions about gender identity, gender dysphoria, standard practices, and safety of gender-affirming medical treatments'. The white paper concluded that the review 'is not an authoritative guideline or standard of care, nor is it an accurate restatement of the available medical evidence on the treatment of gender dysphoria'.


Daily Mail
2 hours ago
- Daily Mail
NHS 'faces hike in drugs prices' as part of government's trade deal with Trump as US president seeks to help Big Pharma
The NHS could see billions added to its annual drugs bill under the trade deal done by Keir Starmer with Donald Trump 's America. The president wants foreign countries to pay more for drugs made in the US to help Big Pharma firms make more money abroad. The health service in England currently uses a drug-pricing scheme that sees drug-makers discount the price of medicine sold in bulk to avoid it busting a £20billion cap. But manufacturers have claimed the system is not viable and risks investment in the UK because it is more expensive than the schemes used by other countries. They pay back almost a quarter of their UK sales to the Government in rebates to avoid busting the cap, far more than the 15 per cent estimated and way above the average 5.7 per cent rebate in France, 7 per cent in Germany and 9 per cent in Ireland. The deal done at the start of May promised the sector 'significantly preferential treatment', with ministers vowing 'to improve the overall environment for pharmaceutical companies operating in the UK'. A White House source told the Telegraph it expected the NHS to start paying more to improve the balance sheets of American firms. Last week the CEO of Pfizer accused the UK and other European nations of 'free-riding all these years' on the back of US-based investment in pharmaceuticals. Albert Bourla told a conference that given US pressure on European countries to pay more, prices there could increase. He suggested the Trump administration should treat the sector like Nato defence spending and demand US allies pay more of their GDP into it. The US is also demanding the UK use fewer cheaper drugs from China, the Telegraph claimed. The President threatened to slap a 25 per cent tariff on UK pharmaceuticals entering the US, which last year totalled £6.6 billion. He also issued an executive order last month directing drugmakers to lower the prices of their medicines to align with what other countries pay. Health Secretary Wes Streeting is reviewing the rebate, which is likely to be wrapped in with ongoing US tariff talks, sources add. The UK spends a smaller share of its overall healthcare costs on medicines than any comparable country, according to the Association of the British Pharmaceutical Industry (ABPI), whose members includeUS drugs giants such as Pfizer, Bristol Myers Squibb, Amgen, Johnson & Johnson, Merck and Biogen.